Latest On aTyr Pharma, Inc (LIFE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 04:27 EST | News | aTyr Pharma GAAP EPS of -$0.29 | N/A |  |
| 2023-03-11 01:11 EST | News | aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-09 18:48 EST | News | aTyr Pharma GAAP EPS of -$0.26 beats by $0.22, revenue of $10.4M beats by $10.15M | N/A | |
| 2023-02-09 12:24 EST | News | aTyr Pharma: The Uncertainty Of Efzofitimod, Analysis Of Clinical Study | N/A | |
| 2023-02-09 12:24 EST | News | aTyr Pharma stock dips after pricing $50M stock offering | N/A | |
| 2023-02-08 23:11 EST | News | aTyr pharma falls 10% on public offering of shares | N/A | |
| 2023-02-06 19:29 EST | News | aTyr gains as late-stage study for lead asset brings $10M payment | N/A | |
| 2023-01-18 08:45 EST | News | ATyr Pharma therapy for lung disorder gets orphan drug status in EU | N/A | |
| 2022-11-11 12:37 EST | News | aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-10 19:11 EST | News | aTyr Pharma GAAP EPS of -$0.46 in-line | N/A | |
| 2022-09-29 12:03 EST | News | aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies | N/A | |
| 2022-09-13 13:35 EST | News | aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease | N/A | |
| 2022-08-17 03:35 EST | News | aTyr pharma stock rises 15% after Q2 results; efzofitimod phase 3 trial enrollment on track | N/A | |
| 2022-08-16 10:03 EST | News | aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-15 17:44 EST | News | aTyr Pharma GAAP EPS of -$0.44 in-line | N/A | |
| 2022-08-12 21:26 EST | News | aTyr Pharma Q2 2022 Earnings Preview | N/A | |
| 2022-08-11 11:44 EST | News | aTyr Pharma gains with FDA Fast Track status for lead asset | N/A | |
| 2022-05-25 19:32 EST | News | aTyr Pharma (LIFE) Investor presentations - Slideshow | N/A | |
| 2022-05-21 08:31 EST | News | aTyr Pharma ATS Conference Presentation May 2022 | N/A | |
| 2022-05-19 04:44 EST | News | aTyr Pharma stock dips after Piper Sandler cuts price target on lung disease drug approval timeline | N/A | |
| 2022-05-10 08:27 EST | News | aTyr Pharma GAAP EPS of -$0.44 misses by $0.11 | N/A | |
| 2022-05-10 08:27 EST | News | aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay S. Shukla on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-08 18:29 EST | News | aTyr Pharma Q1 2022 Earnings Preview | N/A | |
| 2022-04-13 04:42 EST | News | aTyr Pharma up 5% after hours following Orphan Drug Status for efzofitimod | N/A | |
| 2022-03-16 04:24 EST | News | aTyr Pharma files for $200M mixed shelf offering | N/A | |
| 2022-03-15 05:38 EST | News | aTyr Pharma GAAP EPS of -$0.31 misses by $0.03 | N/A | |
| 2022-03-15 05:38 EST | News | aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-12 08:07 EST | News | aTyr Pharma Q4 2021 Earnings Preview | N/A | |
| 2022-03-10 18:13 EST | News | aTyr Pharma to begin registrational trial for lead asset in Q3 2022 | N/A | |
| 2022-01-13 17:18 EST | News | aTyr Pharma's lung disease drug ATYR1923 named efzofitimod | N/A | |
| 2022-01-06 14:37 EST | News | aTyr Pharma's ATYR1923 an Orphan Drug in U.S. for sarcoidosis | N/A | |
| 2021-12-28 10:10 EST | News | aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis | N/A | |
| 2021-11-11 08:33 EST | News | aTyr Pharma EPS beats by $0.15 | N/A | |
| 2021-11-11 08:33 EST | News | aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 11:00 EST | News | aTyr Pharma Q3 2021 Earnings Preview | N/A | |
| 2021-09-25 05:18 EST | News | aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy | N/A | |
| 2021-09-25 05:18 EST | News | aTyr Pharma posts biggest intraday loss in over two years after capital raise | N/A | |
| 2021-09-21 23:01 EST | News | aTyr Pharma rises after success for lead asset in trial for lung disease | N/A | |
| 2021-09-21 22:58 EST | News | aTyr reaches a historic high after success in lung cancer study; Roth raises price target | N/A | |
| 2021-09-21 22:55 EST | News | aTyr Pharma shares under pressure after proposed capital raise | N/A | |
| 2021-09-21 22:55 EST | News | aTyr Pharma plunges on proposed stock offering | N/A | |
| 2021-09-21 22:54 EST | News | aTyr Pharma prices $75M capital raise | N/A | |
| 2021-09-21 22:51 EST | News | Tang Capital Partners discloses 6.3% stake in aTyr Pharma | N/A | |
| 2021-09-21 22:48 EST | News | aTyr Pharma closes $86.3M underwritten public offering | N/A | |
| 2021-08-11 03:39 EST | News | aTyr Pharma EPS misses by $0.15 | N/A | |
| 2021-08-11 03:38 EST | News | aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-29 21:13 EST | News | aTyr Pharma granted U.S. patent covering use of ATYR1923 in lung inflammation | N/A | |
| 2021-07-21 13:49 EST | News | aTyr pharma records last patient visit in early-stage ATYR1923 pulmonary sarcoidosis trial | N/A | |
| 2021-04-10 00:29 EST | News | aTyr Pharma posts preclinical research of ATYR2810 in lung and breast cancer at AACR21 | N/A | |
| 2021-03-24 01:56 EST | News | aTyr Pharma EPS beats by $0.35, beats on revenue | N/A | |
About aTyr Pharma, Inc (LIFE):
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.
General
- Name aTyr Pharma, Inc
- Symbol LIFE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 39
- Last Split Factor1:14
- Last Split Date2019-07-01
- Fiscal Year EndDecember
- IPO Date2015-05-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.atyrpharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 4.89
- Price/Book (Most Recent Quarter) 1.78
- Enterprise Value Revenue 3.1
- Enterprise Value EBITDA 0.01
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.69
- Profit Margin -202%
- Operating Margin -198%
- Return on Assets -25%
- Return on Equity -59%
- Revenue 8.55 million
- Earnings Per Share -$10.21
- Revenue Per Share $1.15
- Gross Profit -13626000
- Quarterly Earnings Growth -19.6%
View More
Highlights
- Market Capitalization 53.58 million
- EBITDA -23464000
- PE Ratio -2.12
- Analyst Target Price $15
- Book Value Per Share $3.22
View More
Share Statistics
- Shares Outstanding 10.19 million
- Shares Float 8.42 million
- % Held by Insiders 525%
- % Held by Institutions 64.57%
- Shares Short 297643
- Shares Short Prior Month 159766
- Short Ratio 0.17
- Short % of Float 3%
- Short % of Shares Outstanding 3%
View More
Technicals
- Beta 2.02
- 52 Week High $7.93
- 52 Week Low $2.4
- 50 Day Moving Average 5
- 200 Day Moving Average 4.07
View More
Dividends
- Dividend Date 2019-07-01
- ExDividend Date N/A
- Dividend Yield 0%
View More
aTyr Pharma, Inc (LIFE) Dividend Calendar:
LIFE's last dividend payment was made to shareholders on July 1, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
aTyr Pharma, Inc (LIFE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-12 | $148000 | -$0.68 | -$0.74 | 8.52% |
| 2020-06-30 | 2020-08-13 | $N/A | -$0.69 | -$0.73 | 5.48% |
| 2020-03-31 | 2020-05-12 | $8.07 million | $0.25 | -$0.18 | 238.89% |
| 2019-12-31 | 2020-03-26 | $144000 | -$1.54 | -$1.48 | -4.05% |
| 2019-09-30 | 2019-11-14 | $184000 | -$1.47 | -$1.73 | 14.87% |
| 2019-06-30 | 2019-08-14 | $94000 | -$1.80 | -$2.74 | 34.35% |
| 2019-03-31 | 2019-05-13 | $N/A | -$2.52 | -$3.17 | 20.5% |
| 2018-12-31 | 2019-03-25 | $N/A | -$2.94 | -$3.42 | 14.04% |
| 2018-09-30 | 2018-11-13 | $N/A | -$3.36 | -$4.06 | 17.24% |
| 2018-06-30 | 2018-08-14 | $N/A | -$4.90 | -$4.69 | -4.48% |
| 2018-03-31 | 2018-05-14 | $N/A | -$5.04 | -$4.93 | -2.33% |
| 2017-12-31 | 2018-03-19 | $N/A | -$5.46 | -$5.78 | 5.57% |
| 2017-09-30 | 2017-11-14 | $N/A | -$6.02 | -$7.13 | 15.58% |
| 2017-06-30 | 2017-08-14 | $N/A | -$7.14 | -$8.02 | 10.95% |
| 2017-03-31 | 2017-05-11 | $N/A | -$7.84 | -$7.29 | -7.61% |
| 2016-12-31 | 2017-03-16 | $N/A | -$7.42 | -$8.74 | 15.09% |
| 2016-09-30 | 2016-11-14 | $N/A | -$8.12 | -$9.55 | 14.95% |
| 2016-06-30 | 2016-08-10 | $N/A | -$9.10 | -$9.78 | 6.97% |
| 2016-03-31 | 2016-05-11 | $N/A | -$9.52 | -$10.36 | 8.11% |
| 2015-12-31 | 2016-03-30 | $N/A | -$9.80 | -$7.85 | -24.8% |
| 2015-09-30 | 2015-11-10 | $N/A | -$0.48 | -$0.48 | 0% |
| 2015-06-30 | 2015-08-12 | $N/A | -$0.74 | -$0.53 | -39.62% |
| 2015-03-31 | 2015-05-12 | $N/A | -$9.39 | -$0.41 | -2190.24% |
aTyr Pharma, Inc (LIFE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
aTyr Pharma, Inc (LIFE) Chart:
aTyr Pharma, Inc (LIFE) News:
Below you will find a list of latest news for aTyr Pharma, Inc (LIFE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
aTyr Pharma, Inc (LIFE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.03 | CALL | 0 | 541 | 142.07 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.01 | CALL | 0 | 19 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.25 | PUT | 0 | 5 | 229.22 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 3.8 | PUT | 0 | 0 | 1215.34 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 531.61 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.15 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 197.64 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 258.7 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 421.53 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.15 | CALL | 0 | 675 | 105.33 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0.4 | CALL | 0 | 160 | 191.21 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0.05 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 1.1 | PUT | 0 | 76 | 105.71 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 172.02 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 247.53 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.38 | CALL | 0 | 108 | 126.8 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0.5 | CALL | 0 | 154 | 174.98 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0.2 | CALL | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.9 | PUT | 0 | 5 | 121.08 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 469.89 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 168.03 | TRUE | 0 | 0 |
Latest LIFE Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:47 PM EST | 20 | $2.635 |
| Jun 13, 2022 7:55 PM EST | 100 | $2.67 |
| Jun 13, 2022 7:57 PM EST | 100 | $2.68 |
| Jun 13, 2022 7:59 PM EST | 12 | $2.67 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.69 |
aTyr Pharma, Inc (LIFE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120038468/0001209191-20-038468-index.htm |
| 2020-09-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1339970/000000000020009034/0000000000-20-009034-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1339970/000031506620000790/0000315066-20-000790-index.htm |
| 2014-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000090514814000228/0000905148-14-000228-index.htm |
| 2014-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000093247114003938/0000932471-14-003938-index.htm |
| 2014-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000101143814000161/0001011438-14-000161-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1339970/000103738920000062/0001037389-20-000062-index.htm |
| 2014-01-29 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000108636414001133/0001086364-14-001133-index.htm |
| 2014-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000110465914010587/0001104659-14-010587-index.htm |
| 2013-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018757/0001127602-13-018757-index.htm |
| 2013-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213021773/0001127602-13-021773-index.htm |
| 2013-08-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213024305/0001127602-13-024305-index.htm |
| 2013-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213026615/0001127602-13-026615-index.htm |
| 2013-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213028325/0001127602-13-028325-index.htm |
| 2013-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760213035342/0001127602-13-035342-index.htm |
| 2014-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001413/0001127602-14-001413-index.htm |
| 2014-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001418/0001127602-14-001418-index.htm |
| 2014-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001650/0001127602-14-001650-index.htm |
| 2014-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001652/0001127602-14-001652-index.htm |
| 2014-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001654/0001127602-14-001654-index.htm |
| 2014-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001656/0001127602-14-001656-index.htm |
| 2014-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001658/0001127602-14-001658-index.htm |
| 2014-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001660/0001127602-14-001660-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002547/0001127602-14-002547-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002551/0001127602-14-002551-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002554/0001127602-14-002554-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002558/0001127602-14-002558-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002560/0001127602-14-002560-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002562/0001127602-14-002562-index.htm |
| 2014-01-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214002564/0001127602-14-002564-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004235/0001127602-14-004235-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004240/0001127602-14-004240-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004246/0001127602-14-004246-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004253/0001127602-14-004253-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004258/0001127602-14-004258-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004261/0001127602-14-004261-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004263/0001127602-14-004263-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004265/0001127602-14-004265-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004267/0001127602-14-004267-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004270/0001127602-14-004270-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004273/0001127602-14-004273-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004275/0001127602-14-004275-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004279/0001127602-14-004279-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004282/0001127602-14-004282-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004289/0001127602-14-004289-index.htm |
| 2014-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004295/0001127602-14-004295-index.htm |
| 2013-06-06 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1073431/000119312513250204/0001193125-13-250204-index.htm |
| 2013-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312513251895/0001193125-13-251895-index.htm |
| 2013-06-07 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1073431/000119312513251896/0001193125-13-251896-index.htm |
| 2013-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312513271151/0001193125-13-271151-index.htm |
| 2013-07-22 | DEFM14A | Definitive proxy statement relating to merger or acquisition | https://www.sec.gov/Archives/edgar/data/1073431/000119312513297289/0001193125-13-297289-index.htm |
| 2013-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312513297368/0001193125-13-297368-index.htm |
| 2013-07-22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1073431/000119312513297369/0001193125-13-297369-index.htm |
| 2013-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312513312534/0001193125-13-312534-index.htm |
| 2013-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1073431/000119312513315192/0001193125-13-315192-index.htm |
| 2013-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312513342205/0001193125-13-342205-index.htm |
| 2013-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312513427700/0001193125-13-427700-index.htm |
| 2013-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1073431/000119312513427932/0001193125-13-427932-index.htm |
| 2014-02-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033495/0001193125-14-033495-index.htm |
| 2014-02-04 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033500/0001193125-14-033500-index.htm |
| 2014-02-04 | POSASR | Post-effective Amendment to an automatic shelf registration statement | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033506/0001193125-14-033506-index.htm |
| 2014-02-04 | POSASR | Post-effective Amendment to an automatic shelf registration statement | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033509/0001193125-14-033509-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033511/0001193125-14-033511-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033512/0001193125-14-033512-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033513/0001193125-14-033513-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033514/0001193125-14-033514-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033518/0001193125-14-033518-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033519/0001193125-14-033519-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033520/0001193125-14-033520-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033521/0001193125-14-033521-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033522/0001193125-14-033522-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033527/0001193125-14-033527-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033533/0001193125-14-033533-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033534/0001193125-14-033534-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033549/0001193125-14-033549-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033561/0001193125-14-033561-index.htm |
| 2014-02-04 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1073431/000119312514033570/0001193125-14-033570-index.htm |
| 2014-02-04 | 15-15D | Suspension of duty to report [Section 13 and 15(d)] | https://www.sec.gov/Archives/edgar/data/1073431/000119312514034909/0001193125-14-034909-index.htm |
| 2014-02-14 | 15-12G | Securities registration termination [Section 12(g)] | https://www.sec.gov/Archives/edgar/data/1073431/000119312514054733/0001193125-14-054733-index.htm |
| 2020-01-27 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1339970/000119312520014827/0001193125-20-014827-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007710/0001209191-20-007710-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007716/0001209191-20-007716-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007719/0001209191-20-007719-index.htm |
| 2020-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120008205/0001209191-20-008205-index.htm |
| 2020-05-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120027949/0001209191-20-027949-index.htm |
| 2020-05-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120027960/0001209191-20-027960-index.htm |
| 2020-05-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120027966/0001209191-20-027966-index.htm |
| 2020-05-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120027974/0001209191-20-027974-index.htm |
| 2020-05-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120027984/0001209191-20-027984-index.htm |
| 2020-05-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120027995/0001209191-20-027995-index.htm |
| 2020-05-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120031886/0001209191-20-031886-index.htm |
| 2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120032780/0001209191-20-032780-index.htm |
| 2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120032784/0001209191-20-032784-index.htm |
| 2020-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120032794/0001209191-20-032794-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120038463/0001209191-20-038463-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120038468/0001209191-20-038468-index.htm |
| 2020-08-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120048698/0001209191-20-048698-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1339970/000120919120049578/0001209191-20-049578-index.htm |
| 2014-02-04 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/1073431/000135445714000015/0001354457-14-000015-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1339970/000138713120001285/0001387131-20-001285-index.htm |
| 2020-02-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1339970/000138713120001876/0001387131-20-001876-index.htm |
| 2014-02-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000151905814000088/0001519058-14-000088-index.htm |
| 2015-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1073431/000151905815000016/0001519058-15-000016-index.htm |
| 2020-02-03 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1339970/000156459020002994/0001564590-20-002994-index.htm |
| 2020-02-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1339970/000156459020002995/0001564590-20-002995-index.htm |
| 2020-02-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1339970/000156459020002996/0001564590-20-002996-index.htm |
| 2020-02-05 | S-1MEF | Registration adding securities to prior Form S-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020003559/0001564590-20-003559-index.htm |
| 2020-02-06 | POS EX | Post-effective amendment adding exhibits to registration statement [Rule 462(d)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020003561/0001564590-20-003561-index.htm |
| 2020-02-06 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020003745/0001564590-20-003745-index.htm |
| 2020-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1339970/000156459020004724/0001564590-20-004724-index.htm |
| 2020-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020007842/0001564590-20-007842-index.htm |
| 2020-03-18 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1339970/000156459020011637/0001564590-20-011637-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020013193/0001564590-20-013193-index.htm |
| 2020-03-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020013208/0001564590-20-013208-index.htm |
| 2020-04-02 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1339970/000156459020014976/0001564590-20-014976-index.htm |
| 2020-04-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020017579/0001564590-20-017579-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020023612/0001564590-20-023612-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020024718/0001564590-20-024718-index.htm |
| 2020-05-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020024729/0001564590-20-024729-index.htm |
| 2020-05-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020025993/0001564590-20-025993-index.htm |
| 2020-05-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020026381/0001564590-20-026381-index.htm |
| 2020-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020026385/0001564590-20-026385-index.htm |
| 2020-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020030026/0001564590-20-030026-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020040004/0001564590-20-040004-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020040057/0001564590-20-040057-index.htm |
| 2020-08-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1339970/000156459020040458/0001564590-20-040458-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1339970/000156459020043349/0001564590-20-043349-index.htm |
| 2020-09-18 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1339970/000156459020044008/0001564590-20-044008-index.htm |
| 2020-09-24 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1339970/000156459020044550/0001564590-20-044550-index.htm |
| 2020-10-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1339970/000156459020045765/0001564590-20-045765-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1339970/000162363220000257/0001623632-20-000257-index.htm |
| 2014-02-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1073431/999999999514000318/9999999995-14-000318-index.htm |
| 2020-02-05 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1339970/999999999520000261/9999999995-20-000261-index.htm |
| 2020-09-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1339970/999999999520002595/9999999995-20-002595-index.htm |
aTyr Pharma, Inc (LIFE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of aTyr Pharma, Inc (LIFE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 525%Institutional Ownership: 6457%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2014-02-03 | BALAKRISHNAN S IYER | Director | Sell | 8,888.00 | 76.13 | 676,654.11 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004253/0001127602-14-004253-index.htm |
| 2014-02-03 | DAVID C UPRICHARD | Director | Sell | 2,930.00 | 76.13 | 223,064.42 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004267/0001127602-14-004267-index.htm |
| 2014-02-03 | David F Hoffmeister | Chief Financial Officer | Sell | 84,804.00 | 76.13 | 6,456,230.28 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004275/0001127602-14-004275-index.htm |
| 2014-02-03 | GEORGE F JR ADAM | Director | Sell | 2,747.00 | 76.13 | 209,132.41 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004235/0001127602-14-004235-index.htm |
| 2014-02-03 | GREGORY T LUCIER | Chief Executive Officer | Sell | 456,046.00 | 76.13 | 34,719,329.24 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004282/0001127602-14-004282-index.htm |
| 2014-02-03 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 8,231.00 | 76.13 | 626,635.91 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004273/0001127602-14-004273-index.htm |
| 2014-02-03 | KELLI RICHARD | Chief Accounting Officer | Sell | 5,191.34 | 76.13 | 395,222.94 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004289/0001127602-14-004289-index.htm |
| 2014-02-03 | Mark Stevenson | President & COO | Sell | 122,923.00 | 76.13 | 9,358,275.50 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004295/0001127602-14-004295-index.htm |
| 2014-02-03 | Ora H. Pescovitz | Director | Sell | 5,451.00 | 76.13 | 414,991.17 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004265/0001127602-14-004265-index.htm |
| 2014-02-03 | Peter Michael Leddy | SVP, Global Human Resources | Sell | 41,475.00 | 76.13 | 3,157,541.52 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004279/0001127602-14-004279-index.htm |
| 2014-02-03 | RAYMOND V DITTAMORE | Director | Sell | 23,073.00 | 76.13 | 1,756,575.18 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004240/0001127602-14-004240-index.htm |
| 2014-02-03 | RONALD A MATRICARIA | Director | Sell | 70,000.00 | 76.13 | 5,329,184.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004258/0001127602-14-004258-index.htm |
| 2014-02-03 | RONALD ASBURY ANDREWS | President, Medical Sciences | Sell | 7,357.00 | 76.13 | 560,097.24 | 0.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004270/0001127602-14-004270-index.htm |
| 2020-09-02 | JOHN K CLARKE | Director | Sell | 7,260.00 | 4.01 | 29,112.60 | 110,583.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120049578/0001209191-20-049578-index.htm |
| 2020-08-28 | JOHN K CLARKE | Director | Sell | 100.00 | 4.00 | 400.00 | 117,843.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120049578/0001209191-20-049578-index.htm |
| 2020-08-27 | JOHN K CLARKE | Director | Sell | 5,440.00 | 4.09 | 22,249.60 | 117,943.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120048698/0001209191-20-048698-index.htm |
| 2014-01-07 | JOHN A COTTINGHAM | Chief Legal Officer | Buy | 9,956.48 | 75.85 | 755,199.01 | 12,232.30 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001660/0001127602-14-001660-index.htm |
| 2020-08-26 | JOHN K CLARKE | Director | Sell | 2,200.00 | 4.30 | 9,451.20 | 123,383.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120048698/0001209191-20-048698-index.htm |
| 2020-02-07 | Sanjay Shukla | President and CEO | Sell | 745.00 | 4.03 | 3,002.35 | 1,291.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007719/0001209191-20-007719-index.htm |
| 2013-08-01 | KELLI RICHARD | Chief Accounting Officer | Buy | 1,726.00 | 74.78 | 129,070.28 | 13,480.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213024305/0001127602-13-024305-index.htm |
| 2013-12-18 | Mark Stevenson | President & COO | Buy | 76,000.00 | 22.23 | 1,689,480.00 | 173,260.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213035342/0001127602-13-035342-index.htm |
| 2014-01-07 | Peter Michael Leddy | SVP, Global Human Resources | Buy | 10,072.43 | 75.85 | 763,993.82 | 18,951.95 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001654/0001127602-14-001654-index.htm |
| 2020-02-06 | Sanjay Shukla | President and CEO | Buy | 1,786.00 | 2,036.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007719/0001209191-20-007719-index.htm | ||
| 2014-01-06 | RAYMOND V DITTAMORE | Director | Sell | 5,000.00 | 75.86 | 379,300.00 | 23,073.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001418/0001127602-14-001418-index.htm |
| 2020-05-20 | NANCY DENYES | General Counsel | Sell | 322.00 | 3.62 | 1,165.64 | 2,735.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120032794/0001209191-20-032794-index.htm |
| 2014-01-07 | David F Hoffmeister | Chief Financial Officer | Buy | 12,022.78 | 75.85 | 911,927.86 | 27,465.93 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001650/0001127602-14-001650-index.htm |
| 2013-05-29 | DAVID C UPRICHARD | Director | Sell | 2,010.00 | 74.04 | 148,820.40 | 2,930.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018757/0001127602-13-018757-index.htm |
| 2020-05-16 | NANCY DENYES | General Counsel | Buy | 892.00 | 3,057.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120032794/0001209191-20-032794-index.htm | ||
| 2013-05-24 | JOHN A COTTINGHAM | Chief Legal Officer | Buy | 28,362.00 | 30.53 | 865,891.86 | 36,593.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-28 | JOHN A COTTINGHAM | Chief Legal Officer | Buy | 28,362.00 | 30.53 | 865,891.86 | 36,593.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-09-03 | Peter Michael Leddy | SVP, Global Human Resources | Buy | 2,404.00 | 74.58 | 179,290.32 | 42,730.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213026615/0001127602-13-026615-index.htm |
| 2020-05-20 | PAUL SCHIMMEL | Director | Sell | 8,447.00 | 3.64 | 30,738.63 | 429,143.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120031886/0001209191-20-031886-index.htm |
| 2020-02-10 | PAUL SCHIMMEL | Director | Buy | 254,000.00 | 4.25 | 1,079,500.00 | 437,590.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120008205/0001209191-20-008205-index.htm |
| 2014-01-07 | Mark Stevenson | President & COO | Buy | 19,869.54 | 75.85 | 1,507,104.61 | 47,873.96 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001652/0001127602-14-001652-index.htm |
| 2014-01-07 | KELLI RICHARD | Chief Accounting Officer | Buy | 5,191.34 | 75.85 | 393,763.14 | 5,191.34 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001656/0001127602-14-001656-index.htm |
| 2013-07-01 | Ora H. Pescovitz | Director | Buy | 308.00 | 5,451.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213021773/0001127602-13-021773-index.htm | ||
| 2014-02-03 | Ora H. Pescovitz | Director | Sell | 750.00 | 76.13 | 57,098.40 | 5,451.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214004265/0001127602-14-004265-index.htm |
| 2013-10-01 | Ora H. Pescovitz | Director | Buy | 359.00 | 5,810.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213028325/0001127602-13-028325-index.htm | ||
| 2014-01-03 | Ora H. Pescovitz | Director | Buy | 391.00 | 6,201.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001413/0001127602-14-001413-index.htm | ||
| 2020-02-07 | Jill Marie Broadfoot | Chief Financial Officer | Sell | 375.00 | 4.03 | 1,511.25 | 7,125.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007710/0001209191-20-007710-index.htm |
| 2020-06-19 | Sanjay Shukla | President and CEO | Buy | 6,000.00 | 4.27 | 25,620.00 | 7,291.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120038463/0001209191-20-038463-index.htm |
| 2020-02-06 | Jill Marie Broadfoot | Chief Financial Officer | Buy | 893.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120007710/0001209191-20-007710-index.htm | ||
| 2014-01-07 | GREGORY T LUCIER | Chief Executive Officer | Buy | 50,123.66 | 75.85 | 3,801,879.61 | 81,071.86 | https://www.sec.gov/Archives/edgar/data/1073431/000112760214001658/0001127602-14-001658-index.htm |
| 2013-05-24 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 1,638.00 | 73.86 | 120,982.84 | 8,231.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-24 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 200.00 | 73.87 | 14,774.00 | 8,231.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-28 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 28,362.00 | 74.20 | 2,104,460.40 | 8,231.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-28 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 1,200.00 | 74.25 | 89,094.00 | 8,231.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-24 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 28,162.00 | 73.87 | 2,080,186.13 | 8,431.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2020-06-19 | Jill Marie Broadfoot | Chief Financial Officer | Buy | 1,850.00 | 4.22 | 7,807.00 | 9,153.00 | https://www.sec.gov/Archives/edgar/data/1339970/000120919120038468/0001209191-20-038468-index.htm |
| 2013-05-28 | JOHN A COTTINGHAM | Chief Legal Officer | Sell | 438.00 | 74.24 | 32,517.16 | 9,431.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-24 | JOHN A COTTINGHAM | Chief Legal Officer | Buy | 1,638.00 | 30.53 | 50,008.14 | 9,869.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |
| 2013-05-28 | JOHN A COTTINGHAM | Chief Legal Officer | Buy | 1,638.00 | 30.53 | 50,008.14 | 9,869.00 | https://www.sec.gov/Archives/edgar/data/1073431/000112760213018709/0001127602-13-018709-index.htm |